Literature DB >> 25188932

Use of imiquimod for residual acral melanoma.

Gloria R Sue1, Allison Hanlon1, Rossitza Lazova1, Deepak Narayan2.   

Abstract

Recent reports suggest that topical imiquimod cream is an effective treatment option for certain types of melanomas. No reports exist on the efficacy of using imiquimod cream to treat melanoma located on the plantar surface of the foot. We present two patients with a melanoma of the foot who had residual melanoma following surgical excision with acceptable margins. The patients were then treated with topical imiquimod for 8 weeks after which a repeat biopsy of the affected region showed no evidence of residual melanoma in situ. The use of topical imiquimod cream should be considered in the management of residual melanoma in situ of the plantar surface of the foot. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25188932      PMCID: PMC4154021          DOI: 10.1136/bcr-2014-203826

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Treatment of lentigo maligna with topical imiquimod.

Authors:  M F Naylor; N Crowson; R Kuwahara; K Teague; C Garcia; C Mackinnis; R Haque; C Odom; C Jankey; R L Cornelison
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

Review 2.  Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.

Authors:  Corinne Erickson; Stanley J Miller
Journal:  Int J Dermatol       Date:  2010-05       Impact factor: 2.736

3.  Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.

Authors:  Urs V Buettiker; Nikhil Y Yawalkar; Lasse R Braathen; Robert E Hunger
Journal:  Arch Dermatol       Date:  2008-07

4.  Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot.

Authors:  Jin Young Jung; Hyo Jin Roh; Soo Hyun Lee; Kyoungae Nam; Kee Yang Chung
Journal:  Dermatol Surg       Date:  2011-05-25       Impact factor: 3.398

5.  Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.

Authors:  Anne K Miller; Reginald Dusing; Aaron Meggison; Daniel Aires
Journal:  J Drugs Dermatol       Date:  2011-03       Impact factor: 2.114

6.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

7.  A pilot study of treatment of lentigo maligna with 5% imiquimod cream.

Authors:  C J Fleming; A M Bryden; A Evans; R S Dawe; S H Ibbotson
Journal:  Br J Dermatol       Date:  2004-08       Impact factor: 9.302

8.  Topical imiquimod immunotherapy in the management of lentigo maligna.

Authors:  A M Powell; R Russell-Jones; R J Barlow
Journal:  Clin Exp Dermatol       Date:  2004-01       Impact factor: 3.470

9.  Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.

Authors:  Anne B Bong; Bernd Bonnekoh; Ingolf Franke; Michael P Schön; Jens Ulrich; Harald Gollnick
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

10.  Immunomodulation by imiquimod in patients with high-risk primary melanoma.

Authors:  Rupa Narayan; Hong Nguyen; Jason J Bentow; Lauren Moy; Diana K Lee; Stephanie Greger; Jacquelyn Haskell; Veena Vanchinathan; Pei-Lin Chang; Shanli Tsui; Tamiko Konishi; Begonya Comin-Anduix; Christine Dauphine; Hernan I Vargas; James S Economou; Antoni Ribas; Kevin W Bruhn; Noah Craft
Journal:  J Invest Dermatol       Date:  2011-08-18       Impact factor: 8.551

View more
  1 in total

Review 1.  Melanoma treatment: from conventional to nanotechnology.

Authors:  Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.